4D Molecular Therapeutics/$FDMT
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About 4D Molecular Therapeutics
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
- Ticker
- $FDMT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 196
- Headquarters
- EmeryVille, United States
FDMT Metrics
BasicAdvanced
$718M
-
-$2.77
2.73
-
Price and volume
Market cap
$718M
Beta
2.73
52-week high
$16.93
52-week low
$6.96
Average daily volume
999K
Financial strength
Current ratio
8.033
Quick ratio
7.676
Long term debt to equity
0.083
Total debt to equity
0.096
Profitability
EBITDA (TTM)
-188.89
Gross margin (TTM)
-157.70%
Net profit margin (TTM)
-194.74%
Operating margin (TTM)
-210.76%
Revenue per employee (TTM)
$470,000
Management effectiveness
Return on assets (TTM)
-25.09%
Return on equity (TTM)
-43.25%
Valuation
Price to revenue (TTM)
9.12
Price to book
1.76
Price to tangible book (TTM)
1.76
Price to free cash flow (TTM)
-5.38
Free cash flow yield (TTM)
-18.59%
Free cash flow per share (TTM)
-2.414
Growth
Revenue change (TTM)
278,712.12%
Earnings per share change (TTM)
-21.20%
3-year revenue growth (CAGR)
242.75%
3-year earnings per share growth (CAGR)
-5.35%
What the Analysts think about FDMT
Analyst ratings (Buy, Hold, Sell) for 4D Molecular Therapeutics stock.
Analyst projections of the future price of 4D Molecular Therapeutics stock.
Bulls say / Bears say
Two-year PRISM results showed stable vision and retinal measurements, with 78% fewer supplemental injections than an every-eight-week aflibercept schedule would imply. If larger controlled trials confirm this durability, 4D-150 could materially reduce treatment visits for wet AMD patients. (touchOPHTHALMOLOGY)
Both wet AMD Phase 3 trials have completed enrolment, and 4FRONT-2 finished about four months ahead of plan and enrolled more than expected. The first major efficacy readout is due in Q2 2027, giving investors a defined near-term clinical catalyst. (4D Molecular Therapeutics)
4D-150 has entered Phase 3 testing for DME as well as wet AMD, widening its potential use across two major retinal diseases. The company says the FDA and EMA have agreed that one DME Phase 3 trial, alongside existing clinical data, could support marketing applications. (4D Molecular Therapeutics)
PRISM was a small Phase 2b study, and its injection-burden reductions were compared with a projected dosing schedule rather than a concurrent control group. The Phase 3 trials must show that the benefit holds up in a larger, controlled comparison. (touchOPHTHALMOLOGY)
The DME evidence remains preliminary: the reported two-year efficacy at the Phase 3 dose came from only nine patients, without a control arm. The Phase 3 trial also requires patients to respond to aflibercept, so its results may not apply to those who respond poorly. (Ophthalmology Times)
FDMT remains pre-commercial and its second-quarter net loss widened to $72.9 million as research and development spending rose to $68.3 million. The company reported $430.6 million in cash and expects it to last into the second half of 2028, but ongoing trial costs leave limited room for setbacks or slower progress. (4D Molecular Therapeutics)
Data summarised monthly by Lightyear AI. Last updated on 23 Oct 2026.
FDMT Financial Performance
Revenues and expenses
FDMT Earnings Performance
Company profitability
Upcoming events
No upcoming events
FDMT News
AllArticlesVideos
Funds containing FDMT
Fund name | Fund size | $FDMT weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.3B | 0.04% |
iShares Nasdaq US Biotechnology$BTEC | $1.3B | 0.04% |
Xtrackers S&P 500 Swap£XSPX | $9.1B | 0.03% |
SPDR Russell 2000 US Small Cap€R2US | $5B | 0.02% |
SPDR Russell 2000 US Small Cap£R2SC | $5B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.